Business Context and Reporting Period
This Form 6-K filing by Globavend Holdings Ltd, a Cayman Islands exempted company, covers the month of January 2026. The report details the closing of a registered direct offering that was agreed upon on December 31, 2025, and finalized on January 2, 2026.
Key Financial Metrics
- Gross Proceeds: Approximately $1.4 million raised from the registered direct offering.
- Offering Structure: Sale of 590,648 ordinary shares and pre-funded warrants for up to 298,711 ordinary shares.
- Purchase Price: $1.60 per share for ordinary shares; $1.60 per pre-funded warrant (equivalent to share price less $0.0001 remaining exercise price).
- Placement Agent Fees: 7.0% of aggregate gross proceeds paid to Univest Securities LLC.
- Expense Reimbursement: Up to $25,000 for legal and other expenses incurred by the placement agent.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in share capital and cash liquidity resulting from the registered direct offering. The issuance includes both ordinary shares and pre-funded warrants, the latter utilized to prevent certain purchasers from exceeding a 9.99% beneficial ownership threshold immediately upon closing.
Guidance, Outlook, and Risks
- Lock-Up Provisions: The Company agreed not to issue or announce new equity for 30 days post-closing and is restricted from variable rate transactions for one year.
- Participation Rights: Purchasers have the right to participate in up to 30% of any subsequent equity placement for 24 months following the closing date.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to inherent uncertainties and risks outlined in the Company's Form 20-F.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7% placement fee and expense reimbursements.
- Confirm the total number of outstanding shares post-offering to assess dilution impact.
- Review the specific terms of the pre-funded warrants regarding exercise timing and the $0.0001 remaining exercise price.
- Check the Company's current cash position to understand the significance of the $1.4 million injection relative to working capital needs.